media – Page 572 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

GSK announces positive EU approval for labelling update to Relvar Ellipta in patients with asthma

GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA) combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.
- Source: us.gsk
- 916
- March 12, 2018
asthma EC GSK Relvar Ellipta
Sanofi, Evotec in major infectious disease R&D transfer and license deal

Big Pharma Sanofi and German CRO-biotech drug discovery hybrid Evotec are penning a deal that will see Sanofi license out a host of infectious disease assets to the biotech, with 100 staffers also moving into its R&D engine.
- Source: Fiercebiotech
- 551
- March 12, 2018
infections Market Views R&D
Health app adoption tripled since 2014, Accenture survey finds

Use of telemedicine has gone up as well, but not as dramatically, respondents say.
- Source: HealthcareITNews
- 993
- March 12, 2018
digital health Market Views mHealth
Five tips for exploring pharmaceutical drug export markets

For pharmaceutical companies who want to explore international markets, identifying these target markets is the first step. Being able to pinpoint the right target market, will increase the probability for more business deals. In order to help you with this process, we have listed 5 of the more important aspects to consider.
- Source: Ddu
- 820
- March 9, 2018
Ddu College pharmaceutical
Epigenetic Dysregulation May Be Key to Onset

Greater than 90% of all Alzheimer’s disease (AD) cases are sporadic, meaning there are few hereditary risk factors for developing the disease. Although certain genetic variants increase the risk of AD, age is the strongest known risk factor. Yet, understanding how the underlying molecular mechanisms of aging predispose individuals to AD has remained elusive. Now, a team of researchers from the Perelman School of Medicine at the University of Pennsylvania have discovered what they believe are changes to the normal epigenetic landscape that lead to the onset of Alzheimer’s.
- Source: Pixabay
- 599
- March 9, 2018
Alzheimer's Researches
GlaxoSmithKline’s Fluarix protects young children in large phase 3 test

GSK touted phase 3 data of its quadrivalent flu vaccine Fluarix Tetra. As a severe flu season continues to unfold in the U.S., GlaxoSmithKline is touting phase 3 study data showing its Fluarix Tetra can protect young children who are among the most vulnerable to the virus.
- Source: Fiercepharma
- 764
- March 9, 2018
Clinical Trials flu vaccine
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant Including First-Ever Phase 3 Head-to-Head Superiority Comparison Versus Zolpidem ER in Patients With Sleep Disorder

Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today announced positive topline results from multiple studies of lemborexant, an investigational agent for sleep and wake regulation currently being studied for the treatment of multiple sleep disorders.
- Source: finance.yahoo.
- 542
- March 9, 2018
Clinical Trials Eisai lemborexant multiple sleep disorders
Prometic Snags Rare Pediatric Disease Designation from the FDA for its Inter-Alpha-Inhibitor-Proteins

Shares of Laval, Quebec-based ProMetic Life Sciences Inc. jumped more than 8.7 percent this morning after securing the U.S. Food and Drug Administration’s Rare Pediatric Disease Designation for its Inter-Alpha-Inhibitor-Proteins (IAIP) treatment for necrotizing enterocolitis (NEC).
- Source: biospace
- 615
- March 9, 2018
FDA NEC
J&J CIO touches on FDA pre-cert pilot program, artificial intelligence and innovation

Stuart McGuigan took on his role as CIO of industry behemoth Johnson & Johnson in 2012. That was around the same time that Alex Gorsky joined the company as CEO. Since then, part of Gorsky’s mission has been to help J&J focus on technology, McGuigan said in an interview at HIMSS this week.
- Source: MedCityNews
- 691
- March 9, 2018
AI Company Insight healthcare technologies and innovations
FDA expands approval of replacement heart valve, smallest mechanical valve size approved in the world

The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used in newborn pediatric patients to treat heart defects. Specifically, the agency approved the Masters Series Mechanical Heart Valve with Hemodynamic Plus (HP) Sewing Cuff to include the 15-mm valve size, making it the smallest mechanical heart valve approved in the world.
- Source: FDA
- 650
- March 9, 2018
FDA heart valves medical device New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.